BioCentury Article Highlights GNS Discoveries on Behalf of The MMRF
GNS Healthcare Inc. (Cambridge, Mass.) said it has identified four genes as “top drivers” of high-risk multiple myeloma. Using its machine learning technology, the company is collaborating with the Multiple Myeloma Research Foundation (MMRF) to analyze data in the foundation’s patient-driven, real-world CoMMpass study. Read the full story here.
GenomeWeb Article Offers Insight on GNS-Celgene Deal and Growing Demand for Causal Modeling
GNS Healthcare and Celgene have signed a service and license arrangement that allows the biopharma firm to use GNS Healthcare’s causal machine-learning and simulation platform for applications in drug discovery, clinical development, and commercialization and market access. Read the full story here.
Outsourcing Pharma Puts Spotlight on Power of Causality, Highlights GNS-Celgene Deal Licensing REFS
Celgene has made a second investment in a machine learning and simulation platform for applications across drug discovery, clinical development, and commercialization. Read the full story here.
Discoveries by GNS Healthcare Causal Machine Learning and Simulation Platform, REFS, Reveal Mechanisms Driving Key Clinical Outcomes in Multiple Myeloma
Ongoing Collaboration Leveraging the Multiple Myeloma Research Foundation CoMMpass Study Reveals Drivers of High-Risk Disease and of Durable Response CAMBRIDGE, Mass. – December 6, 2016 – GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual […]
Celgene Enters Into Service and License Arrangement for GNS Healthcare’s Causal Machine Learning Platform to Accelerate Value-Based and Precision Medicine Development
CAMBRIDGE, Mass. – November 29, 2016 – GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual patients, today announced that Celgene Corporation has entered into a service and license arrangement for the rights to […]
MS News Today Features GNS ‘Efficacy to Effectiveness’ Solution
GNS Healthcare is presenting a data-driven causal machine learning solution, called Efficacy to Effectiveness, designed to predict how potential therapies will actually perform in distinct populations. Read the complete story here.
GNS REFS™ Causal Machine Learning Platform Featured in GEN (Genetic Engineering & Biotechnology News)
GNS Healthcare’s causal machine learning platform REFS (Reverse Engineering , Forward Simulation) turns healthcare data into actionable insights to guide precision medicine and scientific discovery. “We reverse engineer causal models from healthcare data,” explains Diane Wuest, Ph.D., associate director, precision medicine initiatives, GNS Healthcare. “Once these models are built, they can be forward simulated and queried […]
BioTelemetry, Inc. (NASDAQ:BEAT) Appoints Colin Hill to Board of Directors
GNS CEO Colin Hill has been named to the Board of Directors of BioTelemetry, Inc., the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. “Mr. Hill’s impressive leadership experience in machine learning in the precision medicine and managed care industries will […]
GNS Healthcare Study with Pfizer Reveals Discovery of Novel Clinical Risk Factors Driving Progression to Type 2 Diabetes and Prediabetes
Published by the Journal of Diabetes Science and Technology, Discoveries Result From Computer Models Created From EHR Data and Causal Machine Learning Technology CAMBRIDGE, Mass. – Feb. 29, 2016 – GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to match health interventions to individual patients and discover new intervention […]
CNBC’s Squawk Box Calls on GNS CEO Colin Hill to Understand Use of Big Data in Employee Wellness
Prompted by a Wall Street Journalarticle, CNBC’s Squawk Box Invited GNS CEO Colin Hill to explain the value of big data and machine learning-enabled employee wellness programs and to address concerns about privacy. Watch the segment here.